Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Nintedanib in Post-COVID Interstitial Lung Disease: a double-blind, randomized, placebo-controlled Clinical Trial.
Journal: Annals of the American Thoracic Society
Published: January 05, 2026
Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis.
Journal: Respiratory research
Published: October 03, 2025
Correction: The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis.
Journal: Respiratory research
Published: May 15, 2025
The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis.
Journal: Respiratory research
Published: April 09, 2024
Objective measurement of cough in pulmonary fibrosis: a cohort study - ImpaCT.
Journal: ERJ open research
Published: March 28, 2024
Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial.
Journal: BMJ open respiratory research
Published: January 18, 2024
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Journal: Respiratory research
Published: September 28, 2022
Provider Perspectives on and Access to Palliative Care for Patients With Interstitial Lung Disease.
Journal: Chest
Published: December 18, 2021
Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry.
Journal: Chest
Published: December 13, 2021
Clinical characteristics associated with small airways disease in systemic sclerosis.
Journal: Journal of scleroderma and related disorders
Published: September 29, 2021
Last Updated: 09/26/2026